The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.405%)
Open: 38.00
High: 38.00
Low: 38.00
Prev. Close: 38.00
MIG1 Live PriceLast checked at -
Maven Income and Growth VCT is an Investment Trust

To achieve long term capital appreciation and generate maintainable levels of income for shareholders through investing in small and medium sized unlisted and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

17 Jan 2014 10:28

RNS Number : 9352X
Maven Income & Growth VCT PLC
17 January 2014
 



Maven Income and Growth VCT PLC (the Company)

 

Interim Management Statement - quarter ended 30 November 2013

 

This Interim Management Statement, for the quarter ended 30 November 2013, is provided in accordance with Rule 4.3 of the Disclosure and Transparency Rules of the UK Listing Authority and also includes relevant information in respect of the period from 1 December 2013 to the date of this announcement. This statement has been prepared solely to provide additional information in order to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders, or any other party, for any other purpose.

 

1.

Financial highlights

 

· Net Asset Value (NAV)1 of 68.3p per share at 30 November 2013, compared to 67.5p per share at 31 August 2013;

· NAV total return2 of 121.4p per share at 30 November 2013, compared to 120.6p per share at 31 August 2013;

· 55,000 Ordinary Shares bought back for cancellation during the quarter; and

· Interim dividend of 2.2p per share in respect of the year ending 28 February 2014, paid on 6 December 2013.

 

1The NAV is unaudited, includes the value of the interim dividend in respect of the year ending 28 February 2014 and reflects the closing bid price of quoted securities as at 30 November 2013. Unlisted companies are normally valued on a six-monthly basis and the NAV incorporates the Directors' valuation of unlisted investments as at 31 August 2013, adjusted for subsequent events where appropriate.

2NAV total return is the sum of NAV per share and dividends paid per share since launch.

 

2.

Investments and disposals

 

During the quarter ended 30 November 2013, a total of £509,878 was invested in four unlisted companies; proceeds of £1,358,454 were received from the disposal of holdings in five unlisted companies, against a total cost of £1,355,401; and the disposal of an AIM quoted holding generated proceeds of £22,878 against an invested cost of £20,789.

 

3.

Offer for Subscription

 

On 24 October 2013, the Company launched an Offer for Subscription with a view to raising up to £4 million of additional capital. The Offer is being made in conjunction with Maven Income and Growth VCT 2 PLC, Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC, each also aiming to raise up to £4 million, and Maven Income and Growth VCT 5 PLC and Maven Income and Growth VCT 6 PLC which are aiming to raise up to £3 million and £1 million respectively.

 

Approval for the issue of shares under the Offer was granted by Shareholders at a General Meeting held on 27 November 2013. It is anticipated that the Offer will remain open until 5 April 2014 in respect of the 2013/14 tax year and until 30 April 2014 in respect of the 2014/15 tax year, unless fully subscribed at an earlier date and subject to the Directors' right to close or extend the Offer at any time. Full terms and conditions of the Offer are set out in the Prospectus which is available at www.mavencp.com/migvct.

 

4.

Recent developments

 

Between 1 December 2013 and the date of this Statement, investments totalling £915,530 were made in two unlisted companies; and capital proceeds of £928,531 were received from one AIM quoted and three unlisted companies, and included £115,010 of consideration relating to two previous disposals.

 

Other than as described above and any changes in the value of investments quoted on regulated markets, the Board is not aware of any material events during the period from 1 September 2013 to 30 November 2013, or in the period from 1 December 2013 to the date of this announcement, which would have had a material impact on the financial position of the Company.

 

Issued on behalf of the Board

 

Maven Capital Partners UK LLP

Secretary

17 January 2014

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGGUQPGUPCGUM
Date   Source Headline
26th Apr 20241:33 pmRNSUnaudited NAV & Proposed Final Dividend
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:47 pmRNSIssue of Equity
27th Mar 202410:34 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
21st Mar 20243:55 pmRNSStatement re Offer for Subscription
20th Mar 20243:44 pmRNSUnaudited Net Asset Value
8th Feb 202410:27 amRNSDirector/PDMR Shareholding
8th Feb 202410:26 amRNSDirector/PDMR Shareholding
8th Feb 202410:08 amRNSIssue of Equity
30th Jan 20245:09 pmRNSTransaction in Own Shares
17th Jan 20249:59 amRNSDirector/PDMR Shareholding
17th Jan 20249:57 amRNSIssue of Equity
15th Jan 20244:25 pmRNSUnaudited Net Value Asset
1st Dec 20239:39 amRNSIssue of Equity
24th Nov 202312:04 pmRNSStatement re Dividend Investment Scheme
9th Nov 20233:35 pmRNSResult of General Meeting
19th Oct 20234:51 pmRNSTransaction in Own Shares
18th Oct 20233:54 pmRNSHalf-year Report
13th Oct 20234:56 pmRNSPublication of a Prospectus
5th Oct 20234:39 pmRNSNet Asset Value and Interim Dividend
20th Jul 20234:32 pmRNSTransaction in Own Shares
14th Jul 20239:26 amRNSIssue of Equity
7th Jul 20234:17 pmRNSStatement re Dividend Investment Scheme
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
6th Jul 20233:37 pmRNSNet Asset Value
6th Jul 20231:06 pmRNSResult of AGM
7th Jun 20234:21 pmRNSAnnual Financial Report
2nd Jun 20239:39 amRNSIssue of Equity
1st Jun 202312:18 pmRNSNet Asset Value(s)
26th May 20233:53 pmRNSTransaction in Own Shares
24th May 202310:52 amRNSUnaudited NAV and Proposed Final Dividend
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
5th Apr 202312:33 pmRNSDirector/PDMR Shareholding
5th Apr 202312:26 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
3rd Mar 202310:37 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 20239:47 amRNSIssue of Equity
21st Feb 20234:39 pmRNSTransaction in Own Shares
6th Feb 20234:23 pmRNSNet Asset Value(s)
2nd Dec 20229:30 amRNSIssue of Equity
25th Nov 202212:36 pmRNSStatement re Dividend Investment Scheme
9th Nov 20222:34 pmRNSResult of General Meeting
4th Nov 202211:15 amRNSHalf-year Report
26th Oct 20223:50 pmRNSTransaction in Own Shares
14th Oct 20223:33 pmRNSNet Asset Value and Interim Dividend
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.